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Auger electron emitting radionuclides in cancer therapy offer the opportunity to deliver a high
radiation dose to the tumor cells with high radiotoxicity while minimizing toxicity to normal tissue.
We have in this study identified the Auger emitter 119Sb as a potent nuclide for targeted radionuclide
therapy based on theoretical dosimetry calculations at a subcellular scale. From these calculations
we have determined the cellular S-values for this therapeutic isotope. Moreover, we have demon-
strated the possibility of producing this isotope and also the SPECT-analogue 117Sb for patient-
specific dosimetry, by measuring the proton irradiation yields for both isotopes using a low-energy
cyclotron. The excellent SPECT imaging properties of the 117Sb radionuclide have been shown by
scanning a Jaszczak SPECT Phantom. © 2008 American Association of Physicists in Medicine.
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In recent years the use of Auger electron emitting radionu-
clides for targeted radionuclide therapy has shown promising
results.1–7 The low-energetic Auger electrons including the
even lower energetic Coster–Kronig CK electrons are emit-
ted by isotopes that decay by electron capture EC or have
internal conversion IC in their decay. Depending on the
isotope, many such electrons can be emitted per decay from
a few to more than 358 almost instantaneously, thus, creat-
ing an electron cascade. The multiplicity and the short range
in tissue from a few nm to some m of these Auger and
CK electrons give rise to a high energy density created in the
immediate vicinity of the decay site and, thus, a high, very
localized absorbed radiation dose to the target region.9 Addi-
tionally, the short range minimizes irradiation of the neigh-
boring, normal cells, resulting in low observed unspecific
radiotoxicities in cell experiments.3,10 The very short range
of the electrons makes the localization of the radionuclides
with respect to the sensitive targets in the cells DNA criti-
cal in determining effects from the radiation. If the decaying
radionuclides are incorporated directly into the nuclear DNA
or in close proximity to the DNA, extreme radiotoxicity is
observed, resembling high-LET radiation with relative bio-
logical effectiveness RBE values much higher than 1.11,12
On the other hand, if the radionuclides are bound outside the
cellular nucleus, e.g., on the cellular membrane, located in
the cytoplasm or extracellular, the effects resemble those ob-
served with low-LET radiation e.g., X-rays with low RBE
values.
Some of the most commonly used Auger emitters for re-
search in radionuclide therapy are 125I, 123I, 111In, 67Ga, and
201Tl, which are all readily obtainable from commercial
sources—the last four isotopes due to their wide use in diag-
3,4,13–15
nostics tracers SPECT in nuclear medicine. How-
3839 Med. Phys. 35 „9…, September 2008 0094-2405/2008/35ever, the wide use of these isotopes in research in the field of
radionuclide therapy is probably more a consequence of this
accessibility than because of optimal radiation physics prop-
erties for cancer therapy.
In principle, the optimal radionuclide for targeted radio-
therapy must be one that, in addition to a proper half-life
hours→days, is emitting radiation with a range that is long
enough to allow irradiation of the target region, but at the
same time, short enough to spare healthy tissue surrounding
this region. Thus, a high proportion of gamma emission as
seen with the four SPECT isotopes mentioned above is an
undesirable property. For dosimetry calculations, however,
the emission of gamma radiation is useful to determine the
time-activity curve for the administered radiopharmaceutical
in, e.g., the critical organs but the gamma intensity should be
low to minimize unwanted dose to healthy tissues. Alterna-
tively, the isotope used for therapy could emit no penetrating
radiation and the time-activity curve and pharmacokinetics
could then be evaluated before the treatment starts or simul-
taneously from a tracer study with a SPECT- or a PET-
isotope of the same element as the one used for the therapy.
Examples of such isotope pairs are 86Y / 90Y and
124I / 131I.16–20
There could be a need for increasing the scarce selection
of available radionuclides suitable for targeted radionuclide
therapy. In this study, we have performed a comparison of
several Auger emitters based on theoretical dosimetry calcu-
lations at subcellular and macroscopic levels. From this we
conclude that the radionuclide 119Sb T1/2=38.19 h is a po-
tent Auger-electron emitter that possibly can be used in
therapy of small metastasis and disseminated cancer cells.
The radionuclide 117Sb T1/2=2.8 h can give SPECT- or
SPECT/CT-based patient-specific 3D dosimetry.
3839„9…/3839/8/$23.00 © 2008 Am. Assoc. Phys. Med.
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evaluate 119Sb for subcellular radioactivity distributions with
the calculation of the cellular S-values for this isotope. As
these results are very encouraging, we have measured the
proton irradiation yields for 119Sb and 117Sb on enriched tar-
get materials. Moreover, we have demonstrated that 117Sb is
very suitable for SPECT imaging by scanning a Jaszczak
SPECT phantom.
II. MATERIALS AND METHODS
II.A. Dose calculations and cellular S-values
The cellular dosimetry was performed using the forma-
lism described in MIRD Cellular S-values21 with a code pro-
grammed in MatLab 7.0.1. Using the geometric reduction
factors by Berger22 Fig. 1 and stopping powers obtained
from an empirical energy-loss expression using the
continuous-slowing down approximation CSDA, the dose
per cumulated decay to all parts of the tumor cell could be
calculated Figs. 3–5. The energy-loss expression, i.e., the
relationship between electron energy E and range R in
unit density matter was taken as experimentally determined
by Cole for energies higher than 0.4 keV.23 Below 0.4 keV,
a fit was made to Cole’s experimental data because these are
not well described by Cole’s expression. The following ex-
pression was used: E=−53 111R3+1491.4R2+11.893R, with
E in keV and R in m. Using this approach, it is assumed
that secondary electrons delta rays are absorbed locally. In
calculating the S-values, this assumption has been shown to
be valid from comparison with Monte Carlo transport codes
for electron energies below several hundred keV.21
The radioactivity in the cell was assumed uniformly dis-
tributed over one of the following spherical symmetric cell
compartments: the cell surface CS, cytoplasm Cy, or cell
nucleus N. As target region, only the cell nucleus was con-
sidered in calculating the S-values. The contribution to the
cellular absorbed mean dose from gamma radiations was not
taken into account since this is negligible as reported in
MIRD Cellular S-values.21
The radiation spectra were either obtained from the Re-
port No. 2 of AAPM Nuclear Task Group No. 6 by Howell,8
if possible, or from the Nuclear Decay Data Files for Dose
Calculation DECDC.24 The spectra from DECDC contain
data for the K-, L-, and M-shell electrons, while the spectra
reported by Howell are more complete by including the low-
Medical Physics, Vol. 35, No. 9, September 2008energy N- and O-shell electrons. The omission of these very
low-energy electrons was seen to be insignificant for sphere
diameters larger than 1 m in agreement with the findings
reported by Howell.8
In calculating the tumor-to-normal-tissue dose ratios
TNDs per disintegration, the dose to the normal tissue was
obtained from the tabulated dose factors DFs, equivalent
to the MIRD organ S-values, in the Radiation dose assess-
ment resource RADAR.25 Only the whole-body to whole-
body dose contribution was considered, i.e., the
Swhole-body←whole-body assuming a uniform activity
distribution in this compartment. The TND calculation was
done on a simple per decay basis, i.e., differences in physical
and biological half-lives and resulting differences in cumu-
lated decays were not taken into account at this stage.
II.B. 119Sb and 117Sb productions
As the above calculations identify 119Sb as a potent iso-
tope for radionuclide therapy, the proton irradiation yields of
this isotope and its SPECT-analogue 117Sb were measured.
II.B.1. Target preparation
The production of the 119Sb and 117Sb radionuclides was
performed via the nuclear reactions: 119Snp,n119Sb and
117Snp,n117Sb, respectively. Before the irradiations, each
enriched tin target enrichment: 97.4% 119Sn and 97.6%
117Sn, respectively, both from Campro Scientific was made
by either dissolving the tin metal 5–30 mg directly in hot
2.5 M KOH containing H2O2 or by dissolving the tin metal
in 0.5 ml hot, concentrated HCl containing H2O2 followed
by adding 1.0 ml 10 M KOH to the solution. The latter route
was used for larger quantities of the tin metal to speed up the
etching process. The resulting solution was then diluted to
0.25 M KOH with distilled water and transferred to an elec-
troplating cell. A coin-like silver plate with a diameter of
29 mm and thickness of 5.2 mm was used as backing see
Fig. 2. The electroplating process was carried out with a
bath temperature of approximately 65–70 °C with a plating
current density of 4–6 mA /cm2 for 6–8 h. The target thick-
nesses of the 117Sn and 119Sn targets were determined from
the weight and surface area of the electroplated tin to be 7.4
2
FIG. 1. The dose to a given point P at radius r is cal-
culated via the geometrical reduction factor
Gr ,rs ,ri ,x. This factor gives the fraction of the
spherical shell centered on P with radius x and thick-
ness dx that lies within the source volume shaded vol-
ume in the figure.and 5.5 mg /cm , respectively.
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The electroplated targets were mounted in a water cooled
irradiation chamber with an aluminium proton energy de-
grader in front of the target. The irradiations were done using
the external proton beam from the beamline of the GE
PETtrace Cyclotron at the Hevesy Laboratory at Risoe Na-
tional Laboratory. The targets were irradiated with a constant
beam current of 15 A with a collimated beam of 10 mm in
diam for 1 h. The integrated beam current was taken as re-
ported by the cyclotron software. The proton energy was
determined from prior irradiations by irradiating a precision
Cu monitor foil. The energy was measured to be 10.1 MeV
behind the energy degrader using the monitor reactions
natCup,x63Zn and natCup,x62Zn with the recommended
cross sections given by IAEA.26
The produced 117Sb activity was measured using a cali-
brated Ge detector Princeton Gamma-Tech, LGC 5 with the
detector software Genie 2000 version 3.0. The energy and
efficiency calibrations were done using 152Eu and 133Ba point
sources AEA Technology. The irradiated target was mea-
sured several times with a distance ranging between 20 cm
and 300 cm from the detector in the time interval from
1 h to 4 days after EOB. The 117Sb activity was determined
primarily from the 158.56 keV -ray I :86% .27 By mea-
suring the target after the 117Sb had decayed, it was possible
to correct the 117Sb activity for any simultaneously produced
117mSn T1/2=13.60 d, which emits a -ray of the same en-
ergy 158.56 keV.
For determining the produced 119Sb activity, a low-energy
Ge detector Canberra, GL0055P was used. This setup made
it possible to discriminate the 23.87 keV -ray stemming
from the 119Sb decay from the characteristic X-rays simulta-
neously emitted from both the 119Sb and impurities with EC
or IC decay, if present. The energy and efficiency calibra-
tions were done using 241Am and 210Pb point sources AEA
Technology. The 119Sb activity was calculated from the
27
FIG. 2. Electroplated tin target 10 mm on a silver backing 29 mm,
5.2 mm thickness.23.87 keV -ray I :16.1%  using Genie 2000. The target
Medical Physics, Vol. 35, No. 9, September 2008was measured several times with a distance of 39 cm from
the detector in the time interval from 52 h to several weeks
after EOB. The long delay between EOB and the first mea-
surement was in order to let the simultaneously produced
107Cd in the silver backing decay. The 119Sb activity was
corrected for any simultaneously produced 119mSn T1/2
=293.1d, which emits a single -ray of the same energy
23.87 keV, by measuring the target after the 119Sb had de-
cayed. The effective attenuation of the 23.87 keV -ray in
the “thick” 119Sn layer was calculated to be 4% and this
correction was included in the activity measurement.
II.C. 117Sb SPECT
To demonstrate the imaging capabilities of the 117Sb iso-
tope, a planar scintigraphy and a single photon emission
computed tomography SPECT scan was made of a Jaszc-
zak SPECT phantom.
II.C.1. 117Sb production
The enriched 117Sn target used in the yield measurements
was irradiated using the setup described above with a 15 A
proton beam 14.9 A mean current for 90 min. After the
TABLE I. The calculated S-values for varying cell sizes with 119Sb activity
uniformly distributed in one of the following cell compartments: N:
Nucleus, Cy: Cytoplasm, or CS: Cell Surface.
Cell size m S-values Gy/Bq s
rC rN SN←N SN←Cy SN←CS
3 1 2.4410−1 5.5010−3 2.1110−3
3 2 3.7210−2 4.1610−3 2.2710−3
4 2 3.7210−2 2.5110−3 1.3210−3
4 3 1.2810−2 2.2310−3 1.4410−3
5 2 3.7210−2 1.7710−3 9.1910−4
5 3 1.2810−2 1.5610−3 9.7710−4
5 4 6.1610−3 1.4510−3 1.0710−3
6 3 1.2810−2 1.2210−3 7.8710−4
6 4 6.1610−3 1.1210−3 7.8210−4
6 5 3.6010−3 1.0310−3 7.8710−4
7 3 1.2810−2 1.0210−3 6.3110−4
7 4 6.1610−3 9.1810−4 5.8710−4
7 5 3.6010−3 8.1610−4 5.6710−4
7 6 2.3410−3 7.3310−4 5.7010−4
8 4 6.1610−3 7.6210−4 4.3510−4
8 5 3.6010−3 6.7110−4 4.1610−4
8 6 2.3410−3 5.8810−4 4.0810−4
8 7 1.6210−3 5.2810−4 4.1410−4
9 4 6.1610−3 6.3310−4 3.0910−4
9 5 3.6010−3 5.5710−4 3.0010−4
9 6 2.3410−3 4.8610−4 2.9510−4
9 7 1.6210−3 4.2710−4 2.9710−4
9 8 1.1710−3 3.8810−4 3.0710−4
10 5 3.6010−3 4.6210−4 2.0610−4
10 6 2.3410−3 4.0410−4 2.0910−4
10 7 1.6210−3 3.5510−4 2.1310−4
10 8 1.1710−3 3.1610−4 2.2010−4
10 9 8.7410−4 2.9210−4 2.3210−4
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HCl with H2O2 added to oxidize the strong reductant, SnII,
to SnIV. This speeds up the etching of the Sn and avoids
reduction of the dissolved SbIII to Sb0 on the silver back-
ing. After the produced 117Sb was dissolved, the radionu-
clidic purity of the resulting solution was measured using the
Ge detector Princeton Gamma-Tech, LGC 5 described
above. Because no radioactive tin impurities were detected in
the solution, no attempt was made to separate the tin and the
produced radioantimony.
II.C.2. Planar scintigraphy and SPECT
The planar scintigraphy PS and the SPECT scan were
both made using the Jaszczak SPECT phantom. The PS was
made of the phantom with the cold rod insert only. The phan-
tom was filled with water containing 202 MBq 117Sb to a
height of 8.8 cm, i.e., to just above the cold rod insert. The
phantom was placed on the collimator face of one of the
detectors of a Philips SKYLight dual-head gamma camera
with medium energy general purpose MEGP collimators
mounted. A total of 10 million counts were acquired.
The SPECT scan was made with the phantom completely
filled with water containing 153 MBq of 117Sb. This time,
both the cold rod insert and the six solid spheres cold spots
were mounted in the phantom. To simulate a hot spot, we
additionally mounted a small cylindrical vial 10 mm,
height 25 mm filled with water containing 15 MBq of 117Sb
offcenter in the volume above the cold rod insert. The phan-
tom was then placed on its side on the bed and scanned. The
acquisition consisted of 32 frames of 30 sec with the MEGP
collimators mounted on the cameras.
The image reconstruction was performed using filtered
backprojection with a Hanning filter followed by standard
attenuation correction. All images were then transferred to
MatLab 7.0.1 for noise reduction and background subtrac-
tion.
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III.A. Cellular S-values and TND
The calculated cellular S-values for 119Sb activity located
on the cell surface, in the cytoplasm, or in the cell nucleus,
respectively, for different sizes of cells and cell nuclei can be
seen in Table I. Plots showing the dose per disintegration
Gy/Bq s as a function of radius for activity in the three
compartments for several different radionuclides are shown
in Figs. 3–5. These plots are for illustrations calculated for
cells with a radius of 8 m and a nucleus radius of
6 m—radii taken for being characteristic values for tumor
cells. Of course, these values can vary between cell popula-
tions and tumor cell types.
For radioactivity bound to the cell membrane or distrib-
uted uniformly in the cytoplasm, it can be seen that 119Sb
clearly delivers the highest dose to the cell nucleus of the
radionuclides tested. The results for the cell membrane
bound activity are in agreement with those reported by Sas-
try et al.28 who calculated that the 20 keV conversion and
K-Auger electrons from 119Sb are optimal for irradiating the
nuclei of cells from radiolabeled monoclonal antibodies
bound to the cell surface. For radioactivity distributed in the
cell nucleus, 119Sb delivers a high dose compared to most of
the radionuclides tested—it is only exceeded by 201Tl and
193mPt.
However, in radionuclide therapy, the effect of a given
treatment is usually limited by the absorbed dose to the criti-
cal organs, i.e., the dose-limiting organs and, thus, it is nec-
essary to include the normal tissue dose.29,30 For very small
tumors and micrometastases with Auger-emitters located in
the cell nuclei, the self-dose is dominating31 and the cross-
dose contribution may then be neglected. Consequently, it
was possible to calculate a tumor-to-normal-tissue dose ratio
TND per disintegration for decays in the tumor cell nuclei
FIG. 3. The dose to various parts of a cell nuclear ra-
dius: 6 m, cellular radius: 8 m per cumulated decay
as a function of radius for a uniform activity distribu-
tion in the cell nucleus.and decays in the total body as described in Sec. II A. The
3843 H. Thisgaard and M. Jensen: 119Sb—A potent Auger emitter for radionuclidetherapy 3843results for different nuclides normalized to the TND value
for 119Sb for cells with a radius of 8 m and a nucleus radius
of 6 m can be seen in Fig. 6.
From Fig. 6 it can be seen that despite the high absorbed
doses delivered to the tumor cell nucleus per disintegration
from 201Tl and 193mPt Fig. 3, their TND values are low
compared to some of the other isotopes tested. This is due to
the abundance of relatively high energy conversion electrons
above 50–100 keV emitted in the decays of these isotopes
with ranges up to more than 0.2 mm in tissue8 in addition to
the abundant photon emission - and especially X-rays
from the 201Tl decay. Based on a theoretical study of differ-
ent isotopes located in varying sizes of spherical tumors in a
patient modeled as an ellipsoid, Bernhardt et al. concluded
that to achieve a high TND in the treatment of small tumorsMedical Physics, Vol. 35, No. 9, September 20081000 cells, the energy of the emitted electrons should be
40 keV.29 In addition, the photon-to-electron energy emis-
sion ratio, p /e, should be 2 the p /e of 201Tl is 2.1. These
statements are in agreement with our findings. For heteroge-
neous radioactivity distributions, which are often seen in
larger tumors, the cross-irradiation component resulting from
these high energy conversion electrons would result in a
more uniform dose distribution, though, and, thus, could be
an advantage. However, it has been shown that in therapy of
neuroendocrine tumors with the Auger- and conversion elec-
tron emitter 111In as 111In-DTPA-Octreotide, it is the Auger
electrons and not the conversion electrons 145–245 keV
that are responsible for the observed therapeutic effects.2
The normalized TND values for activity distributed in the
cytoplasm or on the cell membrane can also be seen in Fig.
FIG. 4. The dose to various parts of a cell nuclear ra-
dius: 6 m, cellular radius: 8 m per cumulated decay
as a function of radius for a uniform activity distribu-
tion in the cell cytoplasm.
FIG. 5. The dose to various parts of a cell nuclear ra-
dius: 6 m, cellular radius: 8 m per cumulated decay
as a function of radius for a uniform activity distribu-
tion on the cell surface.
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cell clusters consisting of a low number of cells due to the
omission of the cross-dose contribution, which starts to ac-
count for a considerable part of the total tumor cell dose
when the cluster size increases.31 In order to calculate the
TND values for larger cell clusters, both the cluster size, the
cluster and cell geometries, and the activity distributions
have to be taken into account. Since the rationale of using
Auger electrons for cancer therapy is to be able to exploit the
possible high-LET-like biological effects, so far only ob-
tained from nuclear localization of the Auger emitter,2,9,12,32
these calculations have not been done in this study.
From Fig. 6 it can be seen that 119Sb has the highest TND
values of the isotopes tested for both nuclear, cytoplasmic,
and membrane bound activity distributions. For the nuclear
distribution 119Sb is closely followed by 125I and 165Er. How-
ever, the long half-life T1/2=59.4 d of 125I is a drawback in
rapid proliferating cells as reported by ODonoghue and
Wheldon33 in combination with the resulting thyroidal up-
take of this isotope if in vivo deiodination occurs.
The use of 165Er for targeted radiotherapy has been sug-
gested recently by Beyer et al.34 Even though it has a p /e
ratio of 4.7 caused by the abundant X-ray emission, and the
dose delivered to the cell nucleus per 165Er disintegration is
quite low compared to the other radionuclides tested, it has a
high TND. For comparison, the p /e ratio for 119Sb is 0.9 the
value of 0.09 reported by Bernhardt et al.29 must be a mis-
print. Thus, 165Er may be another promising radionuclide
for therapy.
Still, of all the radionuclides considered in this study,
119Sb seems to be the most promising radionuclide for tar-
FIG. 6. Calculated tumor-to-normal-tissue dose ratios TNDs per disinte-
gration for decays in different tumor cell compartments N: nucleus, Cy:
cytoplasm, or CS: cell surface and decays in the total body normal tissue.
The results are normalized to the corresponding TND values for 119Sb.
TABLE II. Nuclear data for 117Sb and 123I. Only -ph
Isotope Half-life Decay mode
117Sb 2.80 h EC, 1.7% + 15
123I 13.27 h EC 15
53Medical Physics, Vol. 35, No. 9, September 2008geted radiotherapy of small tumors, micrometastases, or
single cancer cells. This is in good agreement with the theo-
retical study of Bernhardt et al.29 Using predefined criteria
and, as described above, assuming the tumor to be a sphere
and the body an ellipsoid, both with uniform activity distri-
butions, five isotopes were found suitable for targeted radio-
therapy of small tumors, among them 119Sb.
III.B. 117Sb SPECT
Internal dosimetry constitutes a very important part of ra-
dionuclide therapy but because of the absence of penetrating
photon emission from the 119Sb decay, the time-activity
curves and normal-tissue uptake will be difficult to deter-
mine from this radionuclide—the same effect as observed
with 90Y.16 However, by a tracer study with SPECT using
the isotope 117Sb, it should be possible to partly overcome
this. 117Sb decays mainly by EC only 1.7% + with the
emission of the nearly single -ray of 158.56 keV suitable
for imaging. In fact, the energies and intensities of the emit-
ted photons in the 117Sb decay are very similar to the photons
emitted by the widely used SPECT isotope 123I see Table
II.
117Sb can be produced and used for labeling a precursor
using the same technique as for 119Sb. Both isotopes being of
the same element also ensures identical properties in vivo. In
this respect, the isotope pair 117Sb / 119Sb resembles the
86Y / 90Y pair.
From the planar scintigraphy and the transversal slice
corresponding to 1.9 cm through the SPECT tomography
of the Jaszczak phantom Fig. 7, it can be seen that 117Sb is
a suitable imaging isotope. It was possible to locate both the
hot-spot and the three largest spherical cold-spots 38 mm,
31.8 mm, and 25.4 mm in the SPECT scan and all the
cold-rods were visible in the planar scintigraphy. The cold-
rods were not visible in the SPECT scan, though, but this
was primarily due to a too low number of counts in the
separate frames.
III.C. 119Sb and 117Sb production yields
The 119Sb and 117Sb irradiation yields at the end of bom-
bardment EOB were measured to be
1.850.12 MBq /Ah and 34.60.8 MBq /Ah, respec-
tively, using the irradiation conditions and target thicknesses
described in Sec. II B. Based on these measurements and
assuming the use of proper water cooling of the enriched tin
target, one should be able to produce approximately 4.4 GBq
of 119Sb at EOB in 8 h with a low energy cyclotron. This is
with an electroplated target of thickness 50 mg /cm2 in a
with intensities above 0.3% are shown Ref. 27.
Major -lines in keV abundance
86% 5113.4% 861.350.31%
83% 528.961.39% 440.020.43%
0.38% 505.330.32%otons
8.56
8.97
8.54
3845 H. Thisgaard and M. Jensen: 119Sb—A potent Auger emitter for radionuclidetherapy 3845standard 90° target/beam geometry using a collimated
10 mm 11.0 MeV proton beam and a beam current of
35 A. In this extrapolation, we have assumed that the
nuclear cross sections for the 119Snp,n119Sb reaction are
constant in the energy interval 11.0–9.9 MeV represented
by the 50 mg /cm2 target thickness. On the other hand, by
considering the reaction threshold energy of 11.0 MeV for
the 119Snp,2n118Sb reaction,35 one would expect an in-
crease in the cross sections above the 10.1 MeV proton en-
ergy that was used in our yield measurement for the
119Snp,n119Sb reaction. This means that the extrapolated
production yield may be an underestimate of the real obtain-
able yield using the larger amount of enriched target material
than what was used in this study.
If even higher activities are needed, this can be achieved
by either increasing the irradiation time or by a further in-
crease in the target thickness. Another approach is to use an
inclined target/beam geometry to allow a high increase in the
beam current resulting in a considerable increase in the ob-
tainable yield. Such high current irradiations 200 A on
a natSn target using a dedicated PET cyclotron have recently
been performed in our department unpublished data dem-
onstrating the capability of producing several tens of GBqs
of therapeutic isotopes locally. Hence, it will be possible to
produce the amounts of 119Sb radioactivity that is required
for initial patient studies and clinical trials in radionuclide
therapy using a small medical cyclotron.
The shorter half-life of 117Sb and the need for a much
smaller amount of radioactivity for each patient in a diagnos-
tic study than for therapy, makes the 117Sb production less
demanding than the 119Sb production. Using the same ex-
trapolation conditions as above, it will be possible to produce
approximately 23 GBq of 117Sb at EOB in a 4 h irradiation,
which should be sufficient for several patient scans.
IV. CONCLUSION
Based on theoretical dosimetry calculations for different
subcellular distributions of several Auger-electron emitting
isotopes, we have identified 119Sb as being a potent radionu-
clide for targeted radiotherapy of small tumors, microme-
tastases, and single cancer cells. Using the MIRD-model, we
have calculated the cellular S-values for this isotope. In ad-
dition, we have measured the proton irradiation yields for the
production of 119Sb and the corresponding imaging isotope
117Sb using a low-energy cyclotron. From a planar scintigra-
phy and a SPECT scan of a Jaszczak phantom, we have
Medical Physics, Vol. 35, No. 9, September 2008shown that the latter isotope is well suited for SPECT-based
patient-specific dosimetry of an 119Sb-labeled radiopharma-
ceutical. The production yields show that it will be possible
to produce both isotopes with a standard PET-cyclotron in
sufficient quantities for patient imaging and therapy.
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